153 related articles for article (PubMed ID: 38366204)
21. Evaluation of the Clinical Usefulness of BRAFV600E Mutation Analysis of Core-Needle Biopsy Specimens in Thyroid Nodules with Previous Atypia of Undetermined Significance or Follicular Lesions of Undetermined Significance Results.
Choi SH; Baek JH; Lee JH; Choi YJ; Song DE; Chung KW; Kim TY; Shong YK
Thyroid; 2015 Aug; 25(8):897-903. PubMed ID: 25978151
[TBL] [Abstract][Full Text] [Related]
22. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing.
Lee SR; Jung CK; Kim TE; Bae JS; Jung SL; Choi YJ; Kang CS
Thyroid; 2013 Nov; 23(11):1416-22. PubMed ID: 23590130
[TBL] [Abstract][Full Text] [Related]
23. Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study.
Virk RK; Theoharis CG; Prasad A; Chhieng D; Prasad ML
Virchows Arch; 2014 Apr; 464(4):435-42. PubMed ID: 24549591
[TBL] [Abstract][Full Text] [Related]
24. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
Afkhami M; Karunamurthy A; Chiosea S; Nikiforova MN; Seethala R; Nikiforov YE; Coyne C
Thyroid; 2016 Feb; 26(2):242-7. PubMed ID: 26422023
[TBL] [Abstract][Full Text] [Related]
25. Follicular morphological characteristics may be associated with invasion in follicular thyroid neoplasms with papillary-like nuclear features.
Can N; Celik M; Sezer YA; Ozyilmaz F; Ayturk S; Tastekin E; Sut N; Gurkan H; Ustun F; Bulbul BY; Guldiken S; Puyan FO
Bosn J Basic Med Sci; 2017 Aug; 17(3):211-220. PubMed ID: 28453434
[TBL] [Abstract][Full Text] [Related]
26. BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma.
Park JY; Kim WY; Hwang TS; Lee SS; Kim H; Han HS; Lim SD; Kim WS; Yoo YB; Park KS
Endocr Pathol; 2013 Jun; 24(2):69-76. PubMed ID: 23625203
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
28. Expanding the Spectrum of
De Leo A; Serban D; Maloberti T; Sanza V; Coluccelli S; Altimari A; Gruppioni E; Chiarucci F; Corradini AG; Repaci A; Colapinto A; Nannini M; Pantaleo MA; de Biase D; Tallini G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835466
[TBL] [Abstract][Full Text] [Related]
29. Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.
Soares P; Póvoa AA; Melo M; Vinagre J; Máximo V; Eloy C; Cameselle-Teijeiro JM; Sobrinho-Simões M
Endocr Pathol; 2021 Mar; 32(1):44-62. PubMed ID: 33651322
[TBL] [Abstract][Full Text] [Related]
30. miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors.
Titov SE; Ivanov MK; Karpinskaya EV; Tsivlikova EV; Shevchenko SP; Veryaskina YA; Akhmerova LG; Poloz TL; Klimova OA; Gulyaeva LF; Zhimulev IF; Kolesnikov NN
BMC Cancer; 2016 Mar; 16():201. PubMed ID: 26960768
[TBL] [Abstract][Full Text] [Related]
31. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
32. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
Chung KW; Yang SK; Lee GK; Kim EY; Kwon S; Lee SH; Park DJ; Lee HS; Cho BY; Lee ES; Kim SW
Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
[TBL] [Abstract][Full Text] [Related]
33. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of a Two-Year Routine Application of Molecular Testing of Thyroid Fine-Needle Aspirations Using a Seven-Gene Panel in a Primary Referral Setting in Germany.
Eszlinger M; Böhme K; Ullmann M; Görke F; Siebolts U; Neumann A; Franzius C; Adam S; Molwitz T; Landvogt C; Amro B; Hach A; Feldmann B; Graf D; Wefer A; Niemann R; Bullmann C; Klaushenke G; Santen R; Tönshoff G; Ivancevic V; Kögler A; Bell E; Lorenz B; Kluge G; Hartenstein C; Ruschenburg I; Paschke R
Thyroid; 2017 Mar; 27(3):402-411. PubMed ID: 28071986
[TBL] [Abstract][Full Text] [Related]
35. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
[TBL] [Abstract][Full Text] [Related]
36. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
Kwon HJ; Kim EK; Kwak JY
Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
[TBL] [Abstract][Full Text] [Related]
37. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
Rivera M; Ricarte-Filho J; Knauf J; Shaha A; Tuttle M; Fagin JA; Ghossein RA
Mod Pathol; 2010 Sep; 23(9):1191-200. PubMed ID: 20526288
[TBL] [Abstract][Full Text] [Related]
38. Unexpected Widespread Bone Metastases from a BRAF K601N Mutated Follicular Thyroid Carcinoma within a Previously Resected Multinodular Goiter.
Repaci A; Salituro N; Vicennati V; Monari F; Cavicchi O; de Biase D; Ciarrocchi A; Acquaviva G; De Leo A; Gruppioni E; Pagotto U; Tallini G
Endocr Pathol; 2022 Dec; 33(4):519-524. PubMed ID: 34843063
[TBL] [Abstract][Full Text] [Related]
39. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
[TBL] [Abstract][Full Text] [Related]
40. Molecular genotyping of the non-invasive encapsulated follicular variant of papillary thyroid carcinoma.
Kim TH; Lee M; Kwon AY; Choe JH; Kim JH; Kim JS; Hahn SY; Shin JH; Chung MK; Son YI; Ki CS; Yim HS; Kim YL; Chung JH; Kim SW; Oh YL
Histopathology; 2018 Mar; 72(4):648-661. PubMed ID: 28940583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
